Alle Storys
Folgen
Keine Story von AGENNIX AG mehr verpassen.

AGENNIX AG

EANS-News: AGENNIX AG /

Heidelberg (euro adhoc) -

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
6-month report
Agennix AG Schedules Conference Call on
August 5, 2010 to Discuss First Half of 2010 Financial Results
Planegg/Munich (Germany), Princeton, NJ and Houston, TX, July 29, 
2010 - Agennix AG (Frankfurt Stock Exchange: AGX) today announced 
that the Company will hold a conference call to discuss financial 
results for the second quarter and first half of 2010 and to provide 
a business update. The results will be published on Thursday, August 
5, 2010 in advance of the conference call.
The conference call, which will be conducted in English, will be held
on Thursday, August 5, 2010 at 9 AM ET/3 PM CET.
A live webcast will be available on the Agennix Web site at 
www.agennix.com. A replay will be available via the Web site 
following the live event.
Dial-in numbers for the call are as follows:
Participants from Europe:       0049 (0)69 71044 5598
                                0044 (0)20 3003 2666
Participants from the U.S.:     1-646-843-4608
Please dial in 10 minutes before the beginning of the meeting.
About Agennix Agennix AG is a publicly listed biopharmaceutical 
company that is focused on the development of novel therapies to 
improve the length and quality of life of seriously ill patients in 
areas of major unmet medical need. The Company´s most advanced 
program is talactoferrin, an oral therapy that has demonstrated 
activity in randomized, double-blind, placebo-controlled Phase II 
studies in non-small cell lung cancer, as well as in severe sepsis. 
Talactoferrin is currently in Phase III clinical trials in non-small 
cell lung cancer, and Agennix plans to develop this program further 
for the treatment of severe sepsis. Other clinical development 
programs include RGB-286638, a multi-targeted kinase inhibitor in 
Phase 1 testing; the oral platinum-based compound satraplatin; and a 
topical gel form of talactoferrin for diabetic foot ulcers. Agennix´s
registered seat is in Heidelberg, Germany. The Company has three 
sites of operation: Planegg/Munich, Germany; Princeton, New Jersey 
and Houston, Texas. For additional information, please visit the 
Agennix Web site at www.agennix.com.
This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject to 
risks and uncertainties, many of which are beyond our control, that 
could cause future results, performance or achievements to differ 
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could 
differ materially depending on a number of factors, and we caution 
investors not to place undue reliance on the forward-looking 
statements contained in this press release. Forward-looking 
statements speak only as of the date on which they are made and 
Agennix undertakes no obligation to update these forward-looking 
statements, even if new information becomes available in the future.
For further information, please contact:
Agennix AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693 
ir@agennix.com
In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884 
laurie.doyle@agennix.com
Additional media contacts for Europe:
MC Services AG
Phone: +49 (0) 89 210 228 0
Raimund Gabriel 
raimund.gabriel@mc-services.eu
Hilda Juhasz
hilda.juhasz@mc-services.eu
Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325 
lwilliams@troutgroup.com
end of announcement                               euro adhoc

Further inquiry note:

For further information, please contact:

Agennix AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com

In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com

Additional media contacts for Europe:
MC Services AG
Phone: +49 (0) 89 210 228 0

Raimund Gabriel
raimund.gabriel@mc-services.eu

Hilda Juhasz
hilda.juhasz@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com

Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade

Weitere Storys: AGENNIX AG
Weitere Storys: AGENNIX AG
  • 23.07.2010 – 16:46

    EANS-Adhoc: AGENNIX AG /

    ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Loan agreement 23.07.2010 Agennix AG Secures E 15 Million Loan Planegg/Munich (Germany), Princeton, NJ and Houston, TX, July 23, 2010 - Agennix AG (Frankfurt Stock Exchange: AGX) today announced that it has entered into an agreement with one of its major shareholders, ...